Market research
LJPP.F La Jolla Pharmaceutical Company
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 155M
- P/E ratio
- 46.71
- Analyst target
- 4.5
- Dividend yield
- 0.0%
- Beta
- 2.41
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 155M
- P/E ratio
- 46.71
- Analyst target
- 4.5
- Dividend yield
- 0.0%
- Beta
- 2.41
About
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. As of August 22, 2022, La Jolla Pharmaceutical Company operates as a subsidiary of Innoviva, Inc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the LJPP.F discussion.
5 years, 5 months ago
La Jolla Pharmaceutical Company is currently in a long term downtrend where the price is trading 18.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.
La Jolla Pharmaceutical Company's total revenue rose by 51.0% to $11M since the same quarter in the previous year.
Its net income has increased by 86.2% to $-3M since the same quarter in the previous year.
Finally, its free cash flow grew by 57.5% to $-7M since the same quarter in the previous year.
Based on the above factors, La Jolla Pharmaceutical Company gets an overall score of 4/5.